Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immune responses using compositions containing stress proteins

a technology of immune responses and compositions, applied in the direction of antibody medical ingredients, peptide/protein ingredients, peptide sources, etc., can solve the problems of high frequency of viral genome mutations, lack of proof-reading capability of transcriptionase activities responsible for these steps, and high recovery rate, etc., to suppress allergic immune responses, and suppress allergic immune responses

Inactive Publication Date: 2005-09-15
NVENTA BIOPHARMACEUTICALS CORP
View PDF8 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] The invention also relates to vaccines for suppressing allergic immune responses to natural or artificial antigens (allergens) in a mammal, the vaccines including an allergen and all or a portion of a stress protein or all or a protion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to suppress the allergic responses. Any allergen, regardless of whether it is peptidic or not, can be used.
[0020] In one embodiment, the vaccine for suppressing allergic immune responses to natural or artificial antigens (allergens) in a mammal is an allergen chemically conjugated to all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to suppress the allergic responses.
[0021] In another embodiment, the vaccine for suppressing allergic immune responses to natural or artificial antigens (allergens) in a mammal is a recombinant fusion protein which includes an allergen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to suppress the allergic responses.
[0022] In a further embodiment...

Problems solved by technology

The transcriptase activities responsible for these steps lacks proof-reading capability.
Mistakes that are made during transcription and reverse transcription are therefore not repaired, resulting in a high frequency of mutation of the viral genome.
Recovery typically is rapid.
Compromised individuals are prone to suffer secondary infections with bacterial pathogens that cause pneumonia.
These vaccines are not completely effective in providing protective immunity.
This may explain why the vaccines are only incompletely effective; they are susceptible to continuous antigenic variation in these surface proteins.
While tumor-associated antigens are known to induce a host immune response, the response is typically insufficient to be therapeutically effective.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune responses using compositions containing stress proteins
  • Immune responses using compositions containing stress proteins
  • Immune responses using compositions containing stress proteins

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation of Recombinant Stress Proteins

[0086] A. Recombinant Mycobacterial Hsp70. Plasmid Y3111 contains an M. tuberculosis Hsp70 gene functionally inserted between expression control sequences. (Mehlert, A. and Young, D. B., Mol. Microbiol., 3:125-130 (1989). E. coli strain CG2027 (obtained from C. Georgopoulos, University of Geneva, Switzerland) containing a truncated Hsp70 gene was transformed with plasmid Y3111 by standard procedures. (Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)).

[0087] Bacteria containing plasmid Y3111 were grown overnight in 2×YT medium (20 g Tryptone, 10 g yeast extract, 10 g NaCl per liter) containing 100 microgram / ml ampicillin at 37° C., with agitation (250 rpm). A 10% glycerol stock was prepared from this culture and was stored at −70° C. Several scrapings from the frozen glycerol stock were used to inoculate a large culture that was incubated as before for about 48 h. When th...

example 2

CTL response to a Composition Comprising a Mixture of an NP Peptide and hsp70

[0101] a. Preparation of hsp70 and NP peptide Hsp 70, here M. tuberculosis hsp71, was prepared as described in example 1. NP peptide (referred to herein as NP.B; Motal, U. M. A., et al., Eur. J. Immunol., 25:1121-1124 (1995) and references therein) with the amino acid sequence VQLASNENMETM (SEQ ID NO: 1) corresponding to residues 363-374 in the complete NP and containing a known CTL epitope (H-2b-restricted) was produced synthetically (0.25 mM scale) on an Applied Biosystems model 431A peptide synthesizer using Fmoc (9-fluorenylmethyloxycarbonyl) as the alpha-amino protective group and HMP (Wang) resin as the solid support. All amino acid and synthesis chemicals were purchased from Applied biosystems.

[0102] NP.B was cleaved off the support and side-chain-protecting groups were removed by incubating under continuous agitation NP.B-resin for 3 h in 2 ml of a mixture prepared by combining 10 ml trifluoroacet...

example 3

CTL Response to a Composition Comprising a Chemical Conjugate of an NP Peptide and hsp70

a. Preparation of hsp70 and NP Peptide

[0106]M. tuberculosis hsp71 was prepared as described in Example 1. NP.B peptide was synthesized as discussed in Example 2, except that the peptide contained an extra amino-terminal cysteine residue and, thus, had the amino acid sequence CVQIASNENMETM (SEQ ID NO: 2).

b. Chemical Conjugation of Np.B Peptide to hsp70 and Diphtheria Toxoid

[0107] Conjugations were carried out with both hsp70 and, to provide a standard for comparisons of efficacies of specific stimulation of CTL activity, commonly used carrier protein diphtheria toxoid (abbreviated DT; DT was obtained from a commercial source).

b.1. Activation of M. tuberculosis hsp71 and DT Carrier Proteins

[0108] Nine mg of hsp71 were dissolved in 4.5 ml of 0.1 M sodium borate buffer, pH 8.0. Sulfo-MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester) (2.3 mg in 100 ul dimethyl sulfoxamine) was added to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Immunogenicityaaaaaaaaaa
Stress optical coefficientaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein. The invention also relates to vaccines and composition for suppressing allergic immune responses to allergens comprising an allergen and all or a portion of a stress protein.

Description

RELATED APPLICATIONS [0001] This application is a Continuation-in-Part of U.S. application Ser. No. 08 / 756,621, filed Nov. 26, 1996, the entire teachings of which are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] The viruses causing influenza have been arbitrarily named as influenza type A, B, and C. These types define antigenically distinct viruses. Each type has, several distinct subtypes. Viruses within one type are genetically compatible in the sense that cells infected with two different subtypes can assemble mixed viruses containing components from both subtypes. Influenza viruses are classified as orthomyxoviruses. The viruses form particles of between 80 and 120 nm in diameter. Influenza viruses are enveloped viruses, i.e., their outer surface is derived from host cell membrane. Inserted in and protruding from the envelope are two major viral-encoded proteins, hemagglutinin (HA) and neuraminidase (NA). Influenza viruses are negative-stranded RNA viruses...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/00A61K39/00A61K47/48C07K14/11C07K14/35
CPCA61K38/00A61K39/00C07K14/005C07K14/35C07K2319/00C12N2760/16122Y10S530/826Y10S530/825A61K47/646
Inventor MIZZEN, LEEANTHONY, LAWRENCEWU, HUACHENGSIEGEL, MARVIN
Owner NVENTA BIOPHARMACEUTICALS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com